Kezar Life Sciences

Inactive

KZR (NGM)

Kezar Life Sciences is a clinical‑stage biotechnology company focused on discovering and developing novel small‑molecule therapies for immune‑mediated diseases in the United States. Its lead candidate, zetomipzomib (KZR‑616), is a selective immunoproteasome inhibitor being explored for lupus nephritis, dermatomyositis, and polymyositis, with Phase 1b/2 trials in systemic lupus erythematosus. Founded in 2015, it is based in South San Francisco.